WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017199093) NANOLIPOSOMAL IRINOTECAN FOR USE IN TREATING SMALL CELL LUNG CANCER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/199093 International Application No.: PCT/IB2017/000681
Publication Date: 23.11.2017 International Filing Date: 17.05.2017
IPC:
A61K 31/4745 (2006.01) ,A61P 35/00 (2006.01) ,A61K 9/127 (2006.01)
Applicants: IPSEN BIOPHARM LTD.[GB/GB]; Ash Road, Wrexham Industrial Estate Wrexham GB LL13 9UF, GB
Inventors: ADIWIJAYA, Bambang; US
FITZGERALD, Jonathan, Basil; US
LEE, Helen; US
Agent: CARPMAELS & RANSFORD; One Southampton Row London WC1B 5HA, GB
Priority Data:
62/337,96118.05.2016US
62/345,17803.06.2016US
62/362,73515.07.2016US
62/370,44903.08.2016US
62/394,87015.09.2016US
62/414,05028.10.2016US
62/415,82101.11.2016US
62/422,80716.11.2016US
62/433,92514.12.2016US
62/455,82307.02.2017US
62/474,66122.03.2017US
Title (EN) NANOLIPOSOMAL IRINOTECAN FOR USE IN TREATING SMALL CELL LUNG CANCER
(FR) IRINOTÉCAN NANOLIPOSOMAL UTILISÉ DANS LE TRAITEMENT DU CANCER BRONCHIQUE À PETITES CELLULES
Abstract: front page image
(EN) Novel therapies for the treatment of small cell lung cancer (SCLC) include the administration of an antineoplastic therapy consisting of liposomal irinotecan administered once every two weeks, optionally including the administration of other non-antineoplastic agents to the patient such as the administration of a corticosteroid and an anti-emetic to the patient prior to the administration of the irinotecan liposome.
(FR) La présente invention concerne de nouvelles thérapies pour le traitement du cancer bronchique à petites cellules (CBPC) consistant à administrer un traitement antinéoplasique constitué d'irinotécan liposomal administré une fois toutes deux semaines, comprenant optionnellement l'administration d'autres agents non-antinéoplasiques au patient, par exemple l'administration d'un corticostéroïde et d'un antiémétique au patient avant l'administration du liposome d'irinotécan.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)